Raloxifene 60mg

Dragon Pharma Raloxifene — 60mg Second-Generation SERM for Gyno Reversal

Dragon Pharma Raloxifene delivers 60 mg of Raloxifene Hydrochloride per tablet. This second-generation selective estrogen receptor modulator is engineered for athletes seeking to reverse established gynecomastia rather than merely prevent it.

With superior tissue selectivity over first-generation alternatives, this agent acts as a potent antagonist in mammary tissue while preserving estrogenic benefits in bone and lipid metabolism.

Overview

Raloxifene Hydrochloride is a benzothiophene derivative with high affinity for estrogen receptors. Its tissue-specific activity distinguishes it from other SERMs used in athletic contexts.

In breast and uterine tissue, the compound functions as a pure antagonist. It blocks estradiol from activating growth pathways and actively shrinks existing glandular proliferation.

In bone tissue, Raloxifene exhibits partial agonist activity. This supports bone mineral density preservation, offering long-term skeletal protection during periods of suppressed endogenous hormones.

The favorable lipid profile sets it apart from aromatase inhibitors. It typically lowers total and LDL cholesterol without depressing protective HDL levels.

Dragon Pharma subjects every batch to independent analytical testing. Recent verification confirmed 58.23 mg per tablet, ensuring precise dosing for reliable therapeutic outcomes.

Benefits

• Established Gyno Reversal: Superior to first-generation SERMs at shrinking palpable glandular tissue that has progressed beyond early-stage nipple sensitivity into firm subareolar masses.
• Potent Breast Tissue Antagonism: Blocks estrogen receptors in mammary tissue with high affinity, halting further development and promoting regression of existing growth.
• Bone Density Preservation: Exerts estrogenic agonist effects in bone, supporting mineral density and skeletal integrity during low-estrogen phases.
• Favorable Lipid Support: Lowers total and LDL cholesterol without the HDL suppression common to aromatase inhibitors, supporting cardiovascular health.
• On-Cycle Versatility: Can be introduced during active anabolic protocols without requiring cycle cessation, addressing gyno flare-ups as they emerge.

Main Features

• Precisely dosed 60 mg tablets for standard or split administration
• Second-generation benzothiophene SERM with high receptor affinity
• Tissue-selective antagonism in breast and uterine tissue
• Estrogenic agonist activity in bone and lipid metabolism
• Compatible with on-cycle AI use and PCT protocols
• Independent laboratory verification of tablet potency

Ingredients

Each tablet contains 60 mg of Raloxifene Hydrochloride as the active pharmaceutical ingredient.

Inactive excipients include microcrystalline cellulose, lactose monohydrate, magnesium stearate, and pharmaceutical-grade film-coating agents to ensure tablet stability and consistent dissolution.

All raw materials undergo identity and purity validation prior to compression and packaging.

How to Use

Ingest tablets with water, with or without food. Consistency in daily timing supports stable plasma concentrations throughout the treatment period.

For on-cycle gyno reversal, begin immediately at the first sign of palpable subareolar tissue. Continue alongside an aromatase inhibitor to address the root estrogenic drive.

Store the container in a cool, dry environment between 15–25°C (59–77°F). Protect from moisture and direct light. Keep the desiccant pouch intact.

Dosage

The standard therapeutic dose is 60 mg once daily. This is the clinically established threshold for breast tissue reduction and serves as the recommended starting point.

For severe or stubborn cases unresponsive after 2–3 weeks, an aggressive protocol of 60 mg twice daily may be employed. Limit this higher load to short-term intensive therapy.

A typical reversal course spans 4–8 weeks. Meaningful improvement frequently appears within the first 2–4 weeks. If no regression occurs by week 8, pharmacological resolution is unlikely.

As a mild prophylactic measure, 30 mg daily may suit individuals extremely prone to gynecomastia. However, other agents are more commonly selected for prevention.

Side Effects

Hot flashes are the most frequently reported adverse effect. These reflect altered hypothalamic estrogen signaling and are typically mild and self-limiting.

Some users experience leg cramps or generalized muscle discomfort during the active phase.

Peripheral edema manifesting as mild swelling in the extremities may occur in sensitive individuals.

Like other SERMs, Raloxifene carries a small increased risk of venous thromboembolism. This risk is generally low in healthy, active populations but warrants consideration for those with clotting predispositions.

Transient insomnia and headaches have been reported by a minority of users.

Hepatic enzyme elevations may occur with extended use. Short-term gyno reversal protocols typically avoid significant hepatic stress.

Safety Information

This product is intended exclusively for research purposes and use by qualified male adults under appropriate supervision. It is not suitable for minors, women, or individuals with pre-existing thromboembolic, hepatic, or cardiovascular conditions.

Always pair Raloxifene with an aromatase inhibitor when treating on-cycle gynecomastia. Blocking receptors without suppressing systemic estrogen production addresses only half the problem.

Monitor for signs of deep vein thrombosis including unilateral leg swelling, warmth, or pain. Seek immediate medical evaluation if these develop.

Incorporate into Post-Cycle Therapy stacks alongside Clomid or Enclomiphene without interference. Raloxifene does not suppress hypothalamic-pituitary-testicular axis recovery.

Discontinue immediately and seek medical evaluation if severe headaches, visual disturbances, or chest discomfort develop.